Latest News
McKesson to acquire Precision Medicine Group for approximately USD2.25bn
25 August 2026 - Healthcare services company McKesson Corporation (NYSE:MCK) announced on Tuesday that it has signed a definitive agreement to acquire Precision Medicine Group, a global provider of clinical research and biopharma commercialisation se...
CDT signs SAFE note with Pep'd to expand US peptide market exposure
25 August 2026 - US biopharmaceutical development company CDT Equity Inc. (NASDAQ: CDT) said on Tuesday it has entered into a SAFE note with Pep'd Inc., a US-based peptide business.The instrument will convert into Safe Preferred Stock upon Pep&#...
BreakBio set to enter clinic
25 August 2026 - Personalised cancer immunotherapy company BreakBio Corp announced on Monday that it is entering the clinic next quarter.BreakBio says it is designed for higher efficacy than Moderna's individualised neoantigen therapy (INT). For...
FDA approves Johnson & Johnson's IMAAVY (nipocalimab-aahu) to treat warm autoimmune haemolytic anaemia
25 August 2026 - Healthcare products company Johnson & Johnson (NYSE:JNJ) announced on Monday that the US Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA), a...
Astellas doses first patient in Phase 3 study of ASP2138
25 August 2026 - Japanese pharmaceutical company Astellas Pharma Inc (TSE:4503) announced on Monday that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab as first-line treatment...